Go Pro
NASDAQ:NRXS

NeurAxis 8/11/2026 Earnings Report

NeurAxis logo
$6.79 -0.22 (-3.14%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$6.80 +0.01 (+0.16%)
As of 08/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeurAxis EPS Results

Actual EPS
N/A
Consensus EPS
-$0.32
Beat/Miss
N/A
One Year Ago EPS
N/A

NeurAxis Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

NeurAxis Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NeurAxis Earnings Headlines

NeurAxis Expands Payer Coverage with New Policies
1 Stock to Own by July 31st
A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-known name may be positioned to benefit while the Magnificent 7 stumbles. Smaller, overlooked stocks are showing growing potential to challenge AI's biggest players. One specific ticker stands out heading into that date.tc pixel
NeurAxis Declares Q2 Stock Dividend on Series B
See More NeurAxis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email.

About NeurAxis

NeurAxis (NASDAQ:NRXS) (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements. Its lead programs are designed to modulate key pathways involved in neuronal survival and regeneration, with preclinical and early-stage clinical studies underway to assess safety, pharmacokinetics and proof of concept.

Headquartered in the United States, NeurAxis engages with international partners to support its translational and clinical development activities. The company’s common shares trade on the Nasdaq Stock Market under the ticker symbol NRXS.

View NeurAxis Profile